fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Atovaquone & proguanil HCL

All products: not a benefit

Malarone · DIN 02238151 · 250 mg & 100 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 20, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Malarone · DIN 02238151 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2012-04-24 Health Canada: Marketed since 2002-08-20 · brand MALARONE · ATC P01BB51 PROGUANIL AND ATOVAQUONE · form Tablet · route Oral · ingredients ATOVAQUONE 250 MG, PROGUANIL HYDROCHLORIDE 100 MG · company Glaxosmithkline inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02238151)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02238151). DIN 02238151: Malarone Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 082000010; group id 119; item number 0202; lccId None; manufacturer id GSK Source form: Tab; strength: 250mg & 100mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $6.4767; ministry $4.1308 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02238151 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61542
Interchangeable products
Atovaquone Proguanil · DIN 02421429 · $4.1308 Atovaquone and Proguanil Hydrochloride · DIN 02466783 · $4.1308 Mylan-Atovaquone/Proguanil · DIN 02402165 · $4.1308 Teva-Atovaquone Proguanil · DIN 02380927 · $4.1308
Shortage status: not checked (no credentials)

Other products in the same Health Canada class (P01B): coverage varies; not interchangeable

  • Hydroxychloroquine (Plaquenil): general benefit
  • Mefloquine (Lariam): not a benefit
Other drugs in the same formulary class (08:20 Plasmodicides (Antimalarials)) and how they are covered

Matched class: 08:20 Plasmodicides (Antimalarials)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: HYDROXYCHLOROQUINE SULFATE 08:20 Plasmodicides (Antimalarials)

HYDROXYCHLOROQUINE SULFATE

· 6 products · General benefit · strengths: 200mg · Tab

MEFLOQUINE HCL

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 250mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:20
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:18 Antivirals, 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives, 08:40 Miscellaneous Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications MALARONE (atovaquone and proguanil hydrochloride) is indicated for: • Prevention of Malaria: the prophylaxis of P. falciparum malaria including areas where chloroquine resistance has been reported. • Treatment of Malaria: the treatment of acute, uncomplicated P. falciparum malaria when oral treatment is appropriate. MALARONE has been shown to be effective in areas where P. falciparum may be resistant to some other antimalarials. 1.1. Pediatrics Prophylaxis of Malaria (≥11 kg bodyweight) Based on the data submitted and reviewed by Health Canada, the safety and effectiveness of MALARONE for the prophylaxis of malaria have not been established in children who weigh less than 11 kg (see 14. Clinical Trials); therefore, Health Canada has not authorized an indication for prophylactic use in pediatric patients weighing less than 11 kg. Treatment of Malaria (≥3 years of age OR ≥11 kg bodyweight) Based on the data submitted and reviewed by Health Canada, the safety and effectiveness of MALARONE for treatment of acute, uncomplicated P. falciparum malaria in children under 3 years of age or who weigh less than 11 kg have not been established; therefore, Health Cana… https://pdf.hres.ca/dpd_pm/00083918.PDF PM date: 2026-03-17 Source product: MALARONE; DIN 02238151; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Other review policies

For Malarone: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026